- What is ST Innovative Diagnostics' primary focus?
- ST Innovative Diagnostics focuses on developing a novel blood-based test for monitoring malignancies and predicting relapse across various cancers.
- What is the core technology behind ST Innovative Diagnostics' test?
- The company's proprietary technology measures Fibrinogen Like Protein 2 (FGL2) activity in platelets, enabling non-invasive disease monitoring.
- What clinical evidence supports ST Innovative Diagnostics' technology?
- Proof-of-concept clinical studies have shown a high correlation with PET/CT imaging in Non-Hodgkin's Lymphoma, Prostate Cancer, and Cutaneous T-Cell Lymphoma.
- What are the potential future applications for ST Innovative Diagnostics' technology?
- The technology shows promise for early detection of treatment resistance in NHL patients and is planned to expand to solid tumor monitoring and diagnosis, including Metastatic Colorectal and Pancreatic Cancers.
- When was ST Innovative Diagnostics founded?
- ST Innovative Diagnostics was founded in July 2022.
- What is ST Innovative Diagnostics' current employee count?
- ST Innovative Diagnostics has 1-10 employees.
- What is the total funding raised by ST Innovative Diagnostics to date?
- As of July 2024, ST Innovative Diagnostics has raised a total of $70,000.
- Who is the Chief Science Officer at ST Innovative Diagnostics?
- Esther Rabizadeh is the Chief Science Officer at ST Innovative Diagnostics.
